Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aluminium nicotinate is a small molecule drug that is a derivative of niacin (nicotinic acid), used primarily as a hypolipidemic agent to lower lipid levels in the blood. It consists of an aluminium salt of nicotinic acid and belongs to the class of pyridinecarboxylic acids. Its mechanism is presumed to be similar to other niacin derivatives, which act by reducing hepatic synthesis of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), thereby lowering cholesterol and triglyceride levels. Aluminium nicotinate has been investigated for use in cardiovascular conditions related to dyslipidemia[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aluminium nicotinate.